Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in advanced gastrointestinal cancer
NCT05225844Phase 2Unknown
- Sponsor
- Harbin Medical University
- Start
- Jan 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in gastric cancer (GC), colorectal cancer (CRC), sponsored by Harbin Medical University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05225844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225844.